Fennec Pharmaceuticals Inc. (FENC)
| Market Cap | 172.04M |
| Revenue (ttm) | 170,000 |
| Net Income (ttm) | -19.02M |
| Shares Out | 26.00M |
| EPS (ttm) | -0.75 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 28 |
| Last Price | $6.61 |
| Previous Close | $6.62 |
| Change ($) | -0.01 |
| Change (%) | -0.15% |
| Day's Open | 6.64 |
| Day's Range | 6.50 - 6.70 |
| Day's Volume | 33,305 |
| 52-Week Range | 4.80 - 10.67 |
RESEARCH TRIANGLE PARK, N.C., June 29, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circu...
RESEARCH TRIANGLE PARK, N.C., June 24, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique ...
The FDA has accepted for review Fennec Pharmaceuticals Inc's (NASDAQ: FENC) resubmitted marketing application seeking approval for Pedmark (formulated sodium thiosulfate) to prevent ototoxicity induced ...
~ Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~
Fennec Pharma Refiles Pedmark US Application For Cisplatin-Induced Ototoxicity In Pediatric Patients
Fennec Pharmaceuticals Inc (NASDAQ: FENC) has resubmitted its marketing application to the FDA seeking approval for Pedmark (formulated sodium thiosulfate) for the prevention of ototoxicity (toxic to th...
~ If Approved by the FDA, PEDMARK Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ~ If Approved by the FDA, PEDMARK Stands to Be the First Therapy for t...
~ Fennec Remains on Track to Finalize and Resubmit the New Drug Application for PEDMARK™ to the U.S. Food and Drug Administration in the Second Quarter of 2021 ~
~ Fennec is Working Closely with its Third-Party Drug Product Manufacturer to Finalize the New Drug Application (NDA) Resubmission for PEDMARK™ ~
~ The Company Continues to Work with the FDA and Its Third-Party Drug Product Manufacturer to Fully Address CRL and Prepare NDA Resubmission for PEDMARK™ ~
New York, New York--(Newsfile Corp. - November 2, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Fennec Pharmaceuticals Inc. (NASDAQ: FENC...
NEW YORK, Nov. 2, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. between February 11, 2020 and August 10, 202...
New York, New York--(Newsfile Corp. - November 2, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of F...
New York, New York--(Newsfile Corp. - November 2, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fennec Pharmaceuticals Inc. ("Fennec" o...
Los Angeles, California--(Newsfile Corp. - November 2, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fennec Pharmace...
New York, New York--(Newsfile Corp. - October 30, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between Fe...
LOS ANGELES--(BUSINESS WIRE)---- $FENC #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming November 2, 2020 deadline to file a lead plaintiff motion in the class action file...
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) (NASDAQ: FENC)...
Los Angeles, California--(Newsfile Corp. - October 30, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fennec Pharmaceu...
LOS ANGELES, Oct. 29, 2020 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Middle District of North Caroli...
Los Angeles, California--(Newsfile Corp. - October 29, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fennec Pharmaceu...
NEW YORK--(BUSINESS WIRE)-- #Fennec--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States D...
NEW YORK, Oct. 28, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between February 11, 2020 an...
BENSALEM, Pa., Oct. 28, 2020 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming November 2, 2020 deadline to file a lead plaintiff motion in the class action filed on behal...
Los Angeles, California--(Newsfile Corp. - October 28, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fennec Pharmaceu...
LOS ANGELES, Oct. 27, 2020 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming November 2, 2020 deadline to file a lead plaintiff motion in the class action filed on be...
Los Angeles, California--(Newsfile Corp. - October 27, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fennec Pharmaceu...
New York, New York--(Newsfile Corp. - October 23, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between F...
NEW YORK, Oct. 14, 2020 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class actio...
New York, New York--(Newsfile Corp. - October 12, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between Fe...
NEW YORK, Oct. 9, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between February 11, 2020 and...
New York, New York--(Newsfile Corp. - October 7, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Fe...
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) (NASDAQ: FENC)...
New York, New York--(Newsfile Corp. - October 5, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between Feb...
New York, New York--(Newsfile Corp. - September 28, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between...
LOS ANGELES, Sept. 25, 2020 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Middle District of North Carol...
RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a uni...
New York, New York--(Newsfile Corp. - September 20, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc.
LOS ANGELES, Sept. 17, 2020 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming November 2, 2020 deadline to file a lead plaintiff motion in the class action filed on b...
SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed in the Middle District of North Carolina on behalf of purchasers of Fennec Pharmaceutica...
NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Fennec Pharmaceuti...
New York, New York--(Newsfile Corp. - September 12, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc.
New York, New York--(Newsfile Corp. - September 11, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Fennec Pharmaceuticals Inc.
BENSALEM, Pa.--(BUSINESS WIRE)---- $FENC #classaction--Deadline Reminder:Law Offices of Howard G.
New York, New York--(Newsfile Corp. - September 11, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Fennec Pharmaceuticals Inc.
NEW YORK--(BUSINESS WIRE)--Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action has been filed on behalf of investors that purchased or acquired ...
LOS ANGELES--(BUSINESS WIRE)---- $FENC #FENC--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fennec Pharmaceuticals Inc.
BENSALEM, Pa.--(BUSINESS WIRE)---- $FENC #classaction--INVESTOR ALERT: Law Offices of Howard G.
New York, New York--(Newsfile Corp. - September 7, 2020) - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
NEW YORK--(BUSINESS WIRE)---- $FENC #classaction--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Middle District of North Car...
LOS ANGELES--(BUSINESS WIRE)---- $FENC #FENC--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fennec Pharmaceuticals Inc.
About FENC
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Trian... [Read more...]
| Industry Biotechnology | IPO Date Jun 5, 2001 |
| CEO Rostislav Raykov | Employees 9 |
| Stock Exchange NASDAQ | Ticker Symbol FENC |
Analyst Forecasts
According to 2 analysts, the average rating for FENC stock is "Strong Buy." The 12-month stock price forecast is 13.40, which is an increase of 102.72% from the latest price.